Derleme
BibTex RIS Kaynak Göster

Yıl 2021, Cilt: 2 Sayı: 3, 136 - 145, 22.09.2021

Damla Çınar Sedanur Sarı Hüseyin Alkan Kübra Buket Ay Enes Borcaktepe Ahmet Yiğit Duyum , Sude Sevcan Filikçi Eren Gençer Çağla Senem Serhat Soylu Şeyma Tuna Rabia Tuncer Mehmet Emin Yazıcı Emre Altıntaş Murat Gül

Öz

Kaynakça

  • 1. Ory J, MacDonald L, Langille G. Noninvasive Treatment Options for Peyronie’s Disease. Sex Med Rev. 2020;8(4):603-614.
  • 2. Paulis G, Romano G, Paulis A. Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie’s disease: a retrospective analysis of 309 cases. Res Rep Urol. 2016;8:95-103.
  • 3. Sasso F, Gulino G, Falabella R, D’Addessi A, Sacco E, D’Onofrio A et al. Peyronie’s disease: lights and shadows. Urol Int. 2007;78(1):1-9.
  • 4. Patel DP, Christensen MB, Hotaling JM, Pastuszak AW. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol. 2020;38(2):253-261.
  • 5. Armağan A, Soyupek S, Hoşcan B. Peyronie hastalığının medikal tedavisindeki yenilikler. Androloji Bülteni. 2004;6(17):93-98
  • 6. Hussein AA, Alwaal A, Lue TF. All about Peyronie’s disease. Asian J Urol. 2015;2(2):70-78.
  • 7. Hellstrom WJ, Bivalacqua TJ. Peyronie’s disease: etiology, medical, and surgical therapy. J Androl. 2000;21(3):347-54.
  • 8. Mynderse LA, Monga M. Oral therapy for Peyronie’s disease. Int J Impot Res. 2002;14(5):340-4.
  • 9. Akkus E, Yıldırım Ö. Peyronie hastalığı. In: Doğan HS, editor. Ürolojik Cerrahi Kitabı. İstanbul:Galenos; 2020. p. 289-319
  • 10. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91(6):522-4.
  • 11. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide. 2002;7(4):262-76.
  • 12. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229-44.
  • 13. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int. 2006;97(3):625-33.
  • 14. Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC et al. Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci. 2014;183(3):449-53.
  • 15. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472-7.
  • 16. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190-5.
  • 17. Bremer J. Carnitine--metabolism and functions. Physiol Rev. 1983;63(4):1420-80.
  • 18. Yafi FA, Pinsky MR, Sangkum P, Hellstrom WJ. Therapeutic advances in the treatment of Peyronie’s disease. Andrology. 2015;3(4):650-60.
  • 19. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in theoral therapy of Peyronie’s disease: a preliminary report. BJU Int. 2001;88(1):63-7.
  • 20. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-lcarnitine and intraplaque Verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int. 2002;89(9):895-900.
  • 21. Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22(5):298-309
  • 22. Amasyalı AS. Peyronie hastalığının medikal tedavisinde neler değişti: 2015 güncelleme. Androloji bülteni.2015;17(62): 169-173169-173.
  • 23. Russo GI, Cacciamani G, Cocci A, Kessler TM, Morgia G, Serefoglu EC, et al. Comparative Effectiveness of Intralesional Therapy for Peyronie’s Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. J Sex Med. 2019 Feb;16(2):289-299.
  • 24. Levine LA. Peyronie’s disease: A contemporary review of non-surgical treatment. Arab J Urol. 2013;11(3):278-83.
  • 25. Weidner W, Hauck EW, Schnitker J; Peyronie’s Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-5; discussion 535-6
  • 26. Hellstrom WJ. Medical management of Peyronie’s disease. J Androl. 2009 Jul-Aug;30(4):397-405.
  • 27. Roy J, Carrier S. Acute hepatitis associated with treatment of Peyronie’s disease with potassium para-aminobenzoate (Potaba). J Sex Med. 2008;5(12):2967-9
  • 28. Shaw EJ, Mitchell GC, Tan RB, Sangkum P, Hellstrom WJ. The nonsurgical treatment of peyronie disease: 2013 update. World J Mens Health. 2013;31(3):183-92.
  • 29. Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, Glina S, Hakim L, Sadeghi-Nejad H, Broderick G. Evidence- Based Management Guidelines on Peyronie’s Disease. J Sex Med. 2016;13(6):905-23
  • 30. El-Sakka AI, Salabas E, Dinçer M, Kadioglu A. The pathophysiology of Peyronie’s disease. Arab J Urol. 2013;11(3):272-7.
  • 31. Randhawa K, Shukla CJ. Non-invasive treatment in the management of Peyronie’s disease. Ther Adv Urol. 2019;11:1756287218823671.
  • 32. Asali M, Asali M. Intralesional injection of the calcium channel blocker Verapamil in Peyronie’s disease: A critical review. Arch Ital Urol Androl. 2020;92(3).
  • 33. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunicaalbuginea. J Urol. 2002;168(6):2483-5.
  • 34. Kokab A, Wylie K, Allen P, Shetty A, Davies-South D. Structured Self- Rated Response to Iontophoresis with Verapamil and Dexamethasone in Peyronie’s Disease. Adv Urol. 2014;957013.
  • 35. Hatzimouratidis, K., F. Giuliano, I. Moncada, A. Muneer and A. Salonia. EAU guidelines on erectile dysfunction , premature ejaculation, penile curvature and priapism. 2017. Available at https://uroweb. org/wp-content/uploads/16-Malpdf. Accessed May 20, 2021
  • 36. Zemtsov A, Gaddis M, Montalvo-Lugo VM. Moisturizing and cosmetic properties of emu oil: a pilot double blind study. Australas J Dermatol. 1996;37(3):159-61.
  • 37. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003;167(12):1600-19.
  • 38. Kouoh F, Gressier B, Dine T, Luyckx M, Brunet C, Ballester L, Cazin JC. Antioxidant effects and anti-elastase activity of the calcium antagonist nicardipine on activated human and rabbit neutrophils--a potential antiatherosclerotic property of calcium antagonists? Cardiovasc Drugs Ther. 2002;16(6):515-20.
  • 39. Twidwell J, Levine L. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28(2):41-5.
  • 40. Riedl CR, Sternig P, Gallé G, Langmann F, Vcelar B, Vorauer K et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005;48(4):656-61.
  • 41. Canadian Agency for Drugs and Technologies in Health Rapid Response Reports. The use of the electromotive drug administration system in patients with overactive bladder: A review of the clinical effectiveness, safety, and cost-effectiveness. Ottawa (ON). 2014. Available at https://www.ncbi.nlm.nih.gov/books/NBK253337/. Accessed May 22, 2021
  • 42. Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of Verapamil and dexamethasone versus intra-lesional injection for Peyronie’s disease. Andrology. 2013;1(1):129-32.
  • 43. Valenzuela R, Ziegelmann M, Tokar S, Hillelsohn J. The use of penile traction therapy in the management of Peyronie’s disease: current evidence and future prospects. Ther Adv Urol. 2019;11:1756287219838139.
  • 44. Scroppo FI, Mancini M, Maggi M, Colpi GM. Can an external penis stretcher reduce Peyronie’s penile curvature? Int J Impot Res. 2001;13(4)
  • 45. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468-73.
  • 46. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med. 2009;6(2):558-66.
  • 47. Martínez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11(2):506-15.
  • 48. Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez- Salamanca JI et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie’s disease: a controlled multicentre study. BJU Int. 2019;123(4):694-702.
  • 49. Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T et al. Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled Trial. J Urol. 2019;202(3):599-610.
  • 50. Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178-80.
  • 51. MacDonald LP, Armstrong ML, Lehmann KJ, Acker MR, Langille GM. Outcome analysis of patients with Peyronie’s disease who elect for vacuum erection device therapy. Can Urol Assoc J. 2020;14(9):E428-E431.
  • 52. Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815-21.
  • 53. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. A first prospective, randomized, double-blind, placebocontrolled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56(2):363-9.
  • 54. Özyalvaçlı ME, Metin A. Ekstrakorporeal şok dalga tedavisinin androlojideki yeri. 2016;18(65):74-78.
  • 55. Gokce A, Abd Elmageed ZY, Lasker GF, Bouljihad M, Braun SE, Kim H et al. Intratunical Injection of Genetically Modified Adipose Tissue- Derived Stem Cells with Human Interferon α-2b for Treatment of Erectile Dysfunction in a Rat Model of Tunica Albugineal Fibrosis. J Sex Med. 2015;12(7):1533-44.
  • 56. Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ. Role of collagenase clostridium histolyticum in Peyronie’s disease. Biologics. 2015;9:107- 16.
  • 57. Mills SA, Gelbard MK. Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond. World J Urol. 2020;38(2):269-277.
  • 58. Yousif A, Natale C, Hellstrom WJG. Conservative Therapy for Peyronie’s Disease: a Contemporary Review of the Literature. Curr Urol Rep. 2021;22(2):6.
  • 59. Seftel AD. Re: Self-Report and Clinical Response to Peyronie’s Disease Treatment: Peyronie’s Disease Questionnaire Results from 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies. J Urol. 2016;195(4 Pt 1):1075.
  • 60. Hellstrom WJG, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, Tapscott A et al. Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie’s Disease: Results of a Multi-Institutional Analysis. J Urol. 2019;201(4):777-782.
  • 61. Goldstein I, Lipshultz LI, McLane M, Hu Y, Xiang Q, Liu G et al. Long- Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie’s Disease. J Urol. 2020;203(6):1191-1197.
  • 62. Hoy SM. Collagenase Clostridium Histolyticum: A Review in Peyronie’s Disease. Clin Drug Investig. 2020;40(1):83-92.
  • 63. Anaissie J, Yafi FA, Traore EJ, Sikka SC, Hellstrom WJ. Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie’s disease. Andrology. 2017;5(2):274-277.
  • 64. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522-4.
  • 65. Sadagopan A. A snapshot of intralesional verapamil injection in the treatment of Peyronie’s disease today. Andrologia. 2019 Nov;51(10):e13388.
  • 66. Toscano L Jr, Rezende MV, Mello LF, Paulillo D, Glina S. A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and Verapamil in Peyronie’s Disease: a pilot study. Int Braz J Urol. 2016;42(5):1005-1009.
  • 67. Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y et al. Nicardipine vs. saline injection as treatment for Peyronie’s disease: a prospective, randomized, single-blind trial. J Sex Med. 2010;7(11):3743- 9.
  • 68. Warde N. Therapy: Intralesional Nicardipine: another calcium channel blocker shown to be effective in patients with Peyronie’s disease. Nat Rev Urol. 2010;7(11):596.
  • 69. Castiglione F, Hedlund P. Intratunical injection of human adipose tisse-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease. Eur Urol. 2013;63:551–60

Non-Surgical Treatment Options for Peyronie’s Disease

Yıl 2021, Cilt: 2 Sayı: 3, 136 - 145, 22.09.2021

Damla Çınar Sedanur Sarı Hüseyin Alkan Kübra Buket Ay Enes Borcaktepe Ahmet Yiğit Duyum , Sude Sevcan Filikçi Eren Gençer Çağla Senem Serhat Soylu Şeyma Tuna Rabia Tuncer Mehmet Emin Yazıcı Emre Altıntaş Murat Gül

Öz

Peyronie’s disease, which occurs with the formation of a fibrous plaque in the tunica albuginea; is a disease that causes some physical problems such as bending and shortening of the penis. There are surgical treatment methods of this disease as well as non-surgical treatment methods. Non-surgical treatment methods, which are grouped under six headings: oral treatments, topical treatments, traction and vacuum treatments, shock wave therapy, intraplate injection treatments, and experimental treatments, can be preferred in cases where the symptoms are not very advanced because they provide advantages in terms of ease of application, accessibility, and cost. Although the only non-surgical treatment method approved by the FDA (U.S. Food and Drug Administration) yet is clostridium collagenase histolikum, which is used in intraplaque injection, studies have shown that other methods also reduce curvature, pain, and plaque volume.

Anahtar Kelimeler

Peyronie’s Disease Non-Surgical Treatment Plaque.

Kaynakça

  • 1. Ory J, MacDonald L, Langille G. Noninvasive Treatment Options for Peyronie’s Disease. Sex Med Rev. 2020;8(4):603-614.
  • 2. Paulis G, Romano G, Paulis A. Prevalence, psychological impact, and risk factors of erectile dysfunction in patients with Peyronie’s disease: a retrospective analysis of 309 cases. Res Rep Urol. 2016;8:95-103.
  • 3. Sasso F, Gulino G, Falabella R, D’Addessi A, Sacco E, D’Onofrio A et al. Peyronie’s disease: lights and shadows. Urol Int. 2007;78(1):1-9.
  • 4. Patel DP, Christensen MB, Hotaling JM, Pastuszak AW. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie’s disease. World J Urol. 2020;38(2):253-261.
  • 5. Armağan A, Soyupek S, Hoşcan B. Peyronie hastalığının medikal tedavisindeki yenilikler. Androloji Bülteni. 2004;6(17):93-98
  • 6. Hussein AA, Alwaal A, Lue TF. All about Peyronie’s disease. Asian J Urol. 2015;2(2):70-78.
  • 7. Hellstrom WJ, Bivalacqua TJ. Peyronie’s disease: etiology, medical, and surgical therapy. J Androl. 2000;21(3):347-54.
  • 8. Mynderse LA, Monga M. Oral therapy for Peyronie’s disease. Int J Impot Res. 2002;14(5):340-4.
  • 9. Akkus E, Yıldırım Ö. Peyronie hastalığı. In: Doğan HS, editor. Ürolojik Cerrahi Kitabı. İstanbul:Galenos; 2020. p. 289-319
  • 10. Prieto Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicine in the early stages of Peyronie’s disease. BJU Int. 2003;91(6):522-4.
  • 11. Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J et al. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie’s fibrotic plaque and in its rat model. Nitric Oxide. 2002;7(4):262-76.
  • 12. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie’s fibrotic plaque and related fibroblast cultures. Nitric Oxide. 2003;9(4):229-44.
  • 13. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie’s disease. BJU Int. 2006;97(3):625-33.
  • 14. Ozturk U, Yesil S, Goktug HN, Gucuk A, Tuygun C, Sener NC et al. Effects of sildenafil treatment on patients with Peyronie’s disease and erectile dysfunction. Ir J Med Sci. 2014;183(3):449-53.
  • 15. Chung E, Deyoung L, Brock GB. The role of PDE5 inhibitors in penile septal scar remodeling: assessment of clinical and radiological outcomes. J Sex Med. 2011;8(5):1472-7.
  • 16. Palmieri A, Imbimbo C, Creta M, Verze P, Fusco F, Mirone V. Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie’s disease and erectile dysfunction: results from a prospective randomized trial. Int J Androl. 2012;35(2):190-5.
  • 17. Bremer J. Carnitine--metabolism and functions. Physiol Rev. 1983;63(4):1420-80.
  • 18. Yafi FA, Pinsky MR, Sangkum P, Hellstrom WJ. Therapeutic advances in the treatment of Peyronie’s disease. Andrology. 2015;3(4):650-60.
  • 19. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in theoral therapy of Peyronie’s disease: a preliminary report. BJU Int. 2001;88(1):63-7.
  • 20. Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-lcarnitine and intraplaque Verapamil in the therapy of advanced and resistant Peyronie’s disease. BJU Int. 2002;89(9):895-900.
  • 21. Safarinejad MR. Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie’s disease: a double-blind, placebo-controlled randomized study. Int J Impot Res. 2010;22(5):298-309
  • 22. Amasyalı AS. Peyronie hastalığının medikal tedavisinde neler değişti: 2015 güncelleme. Androloji bülteni.2015;17(62): 169-173169-173.
  • 23. Russo GI, Cacciamani G, Cocci A, Kessler TM, Morgia G, Serefoglu EC, et al. Comparative Effectiveness of Intralesional Therapy for Peyronie’s Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. J Sex Med. 2019 Feb;16(2):289-299.
  • 24. Levine LA. Peyronie’s disease: A contemporary review of non-surgical treatment. Arab J Urol. 2013;11(3):278-83.
  • 25. Weidner W, Hauck EW, Schnitker J; Peyronie’s Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie’s disease: a prospective, placebo-controlled, randomized study. Eur Urol. 2005;47(4):530-5; discussion 535-6
  • 26. Hellstrom WJ. Medical management of Peyronie’s disease. J Androl. 2009 Jul-Aug;30(4):397-405.
  • 27. Roy J, Carrier S. Acute hepatitis associated with treatment of Peyronie’s disease with potassium para-aminobenzoate (Potaba). J Sex Med. 2008;5(12):2967-9
  • 28. Shaw EJ, Mitchell GC, Tan RB, Sangkum P, Hellstrom WJ. The nonsurgical treatment of peyronie disease: 2013 update. World J Mens Health. 2013;31(3):183-92.
  • 29. Chung E, Ralph D, Kagioglu A, Garaffa G, Shamsodini A, Bivalacqua T, Glina S, Hakim L, Sadeghi-Nejad H, Broderick G. Evidence- Based Management Guidelines on Peyronie’s Disease. J Sex Med. 2016;13(6):905-23
  • 30. El-Sakka AI, Salabas E, Dinçer M, Kadioglu A. The pathophysiology of Peyronie’s disease. Arab J Urol. 2013;11(3):272-7.
  • 31. Randhawa K, Shukla CJ. Non-invasive treatment in the management of Peyronie’s disease. Ther Adv Urol. 2019;11:1756287218823671.
  • 32. Asali M, Asali M. Intralesional injection of the calcium channel blocker Verapamil in Peyronie’s disease: A critical review. Arch Ital Urol Androl. 2020;92(3).
  • 33. Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunicaalbuginea. J Urol. 2002;168(6):2483-5.
  • 34. Kokab A, Wylie K, Allen P, Shetty A, Davies-South D. Structured Self- Rated Response to Iontophoresis with Verapamil and Dexamethasone in Peyronie’s Disease. Adv Urol. 2014;957013.
  • 35. Hatzimouratidis, K., F. Giuliano, I. Moncada, A. Muneer and A. Salonia. EAU guidelines on erectile dysfunction , premature ejaculation, penile curvature and priapism. 2017. Available at https://uroweb. org/wp-content/uploads/16-Malpdf. Accessed May 20, 2021
  • 36. Zemtsov A, Gaddis M, Montalvo-Lugo VM. Moisturizing and cosmetic properties of emu oil: a pilot double blind study. Australas J Dermatol. 1996;37(3):159-61.
  • 37. Kinnula VL, Crapo JD. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med. 2003;167(12):1600-19.
  • 38. Kouoh F, Gressier B, Dine T, Luyckx M, Brunet C, Ballester L, Cazin JC. Antioxidant effects and anti-elastase activity of the calcium antagonist nicardipine on activated human and rabbit neutrophils--a potential antiatherosclerotic property of calcium antagonists? Cardiovasc Drugs Ther. 2002;16(6):515-20.
  • 39. Twidwell J, Levine L. Topical treatment for acute phase Peyronie’s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study. Int J Impot Res. 2016;28(2):41-5.
  • 40. Riedl CR, Sternig P, Gallé G, Langmann F, Vcelar B, Vorauer K et al. Liposomal recombinant human superoxide dismutase for the treatment of Peyronie’s disease: a randomized placebo-controlled double-blind prospective clinical study. Eur Urol. 2005;48(4):656-61.
  • 41. Canadian Agency for Drugs and Technologies in Health Rapid Response Reports. The use of the electromotive drug administration system in patients with overactive bladder: A review of the clinical effectiveness, safety, and cost-effectiveness. Ottawa (ON). 2014. Available at https://www.ncbi.nlm.nih.gov/books/NBK253337/. Accessed May 22, 2021
  • 42. Mehrsai AR, Namdari F, Salavati A, Dehghani S, Allameh F, Pourmand G. Comparison of transdermal electromotive administration of Verapamil and dexamethasone versus intra-lesional injection for Peyronie’s disease. Andrology. 2013;1(1):129-32.
  • 43. Valenzuela R, Ziegelmann M, Tokar S, Hillelsohn J. The use of penile traction therapy in the management of Peyronie’s disease: current evidence and future prospects. Ther Adv Urol. 2019;11:1756287219838139.
  • 44. Scroppo FI, Mancini M, Maggi M, Colpi GM. Can an external penis stretcher reduce Peyronie’s penile curvature? Int J Impot Res. 2001;13(4)
  • 45. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie’s disease: a single-center pilot study. J Sex Med. 2008;5(6):1468-73.
  • 46. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie’s disease. Results of a phase II prospective study. J Sex Med. 2009;6(2):558-66.
  • 47. Martínez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L et al. Acute phase Peyronie’s disease management with traction device: a nonrandomized prospective controlled trial with ultrasound correlation. J Sex Med. 2014;11(2):506-15.
  • 48. Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez- Salamanca JI et al. Penile traction therapy with the new device ‘Penimaster PRO’ is effective and safe in the stable phase of Peyronie’s disease: a controlled multicentre study. BJU Int. 2019;123(4):694-702.
  • 49. Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T et al. Outcomes of a Novel Penile Traction Device in Men with Peyronie’s Disease: A Randomized, Single-Blind, Controlled Trial. J Urol. 2019;202(3):599-610.
  • 50. Raheem AA, Garaffa G, Raheem TA, Dixon M, Kayes A, Christopher N et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie’s disease. BJU Int. 2010;106(8):1178-80.
  • 51. MacDonald LP, Armstrong ML, Lehmann KJ, Acker MR, Langille GM. Outcome analysis of patients with Peyronie’s disease who elect for vacuum erection device therapy. Can Urol Assoc J. 2020;14(9):E428-E431.
  • 52. Hatzichristodoulou G, Meisner C, Gschwend JE, Stenzl A, Lahme S. Extracorporeal shock wave therapy in Peyronie’s disease: results of a placebo-controlled, prospective, randomized, single-blind study. J Sex Med. 2013;10(11):2815-21.
  • 53. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M, Mirone V. A first prospective, randomized, double-blind, placebocontrolled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie’s disease. Eur Urol. 2009;56(2):363-9.
  • 54. Özyalvaçlı ME, Metin A. Ekstrakorporeal şok dalga tedavisinin androlojideki yeri. 2016;18(65):74-78.
  • 55. Gokce A, Abd Elmageed ZY, Lasker GF, Bouljihad M, Braun SE, Kim H et al. Intratunical Injection of Genetically Modified Adipose Tissue- Derived Stem Cells with Human Interferon α-2b for Treatment of Erectile Dysfunction in a Rat Model of Tunica Albugineal Fibrosis. J Sex Med. 2015;12(7):1533-44.
  • 56. Peak TC, Mitchell GC, Yafi FA, Hellstrom WJ. Role of collagenase clostridium histolyticum in Peyronie’s disease. Biologics. 2015;9:107- 16.
  • 57. Mills SA, Gelbard MK. Sixty years in the making: collagenase Clostridium histolyticum, from benchtop to FDA approval and beyond. World J Urol. 2020;38(2):269-277.
  • 58. Yousif A, Natale C, Hellstrom WJG. Conservative Therapy for Peyronie’s Disease: a Contemporary Review of the Literature. Curr Urol Rep. 2021;22(2):6.
  • 59. Seftel AD. Re: Self-Report and Clinical Response to Peyronie’s Disease Treatment: Peyronie’s Disease Questionnaire Results from 2 Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies. J Urol. 2016;195(4 Pt 1):1075.
  • 60. Hellstrom WJG, Tue Nguyen HM, Alzweri L, Chung A, Virasoro R, Tapscott A et al. Intralesional Collagenase Clostridium histolyticum Causes Meaningful Improvement in Men with Peyronie’s Disease: Results of a Multi-Institutional Analysis. J Urol. 2019;201(4):777-782.
  • 61. Goldstein I, Lipshultz LI, McLane M, Hu Y, Xiang Q, Liu G et al. Long- Term Safety and Curvature Deformity Characterization in Patients Previously Treated with Collagenase clostridium Histolyticum for Peyronie’s Disease. J Urol. 2020;203(6):1191-1197.
  • 62. Hoy SM. Collagenase Clostridium Histolyticum: A Review in Peyronie’s Disease. Clin Drug Investig. 2020;40(1):83-92.
  • 63. Anaissie J, Yafi FA, Traore EJ, Sikka SC, Hellstrom WJ. Survey of patient and partner satisfaction following collagenase Clostridium histolyticum treatment for Peyronie’s disease. Andrology. 2017;5(2):274-277.
  • 64. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie’s disease. J Urol. 1994;151(6):1522-4.
  • 65. Sadagopan A. A snapshot of intralesional verapamil injection in the treatment of Peyronie’s disease today. Andrologia. 2019 Nov;51(10):e13388.
  • 66. Toscano L Jr, Rezende MV, Mello LF, Paulillo D, Glina S. A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and Verapamil in Peyronie’s Disease: a pilot study. Int Braz J Urol. 2016;42(5):1005-1009.
  • 67. Soh J, Kawauchi A, Kanemitsu N, Naya Y, Ochiai A, Naitoh Y et al. Nicardipine vs. saline injection as treatment for Peyronie’s disease: a prospective, randomized, single-blind trial. J Sex Med. 2010;7(11):3743- 9.
  • 68. Warde N. Therapy: Intralesional Nicardipine: another calcium channel blocker shown to be effective in patients with Peyronie’s disease. Nat Rev Urol. 2010;7(11):596.
  • 69. Castiglione F, Hedlund P. Intratunical injection of human adipose tisse-derived stem cells prevents fibrosis and is associated with improved erectile function in a rat model of Peyronie’s disease. Eur Urol. 2013;63:551–60
Toplam 69 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Klinik Tıp Bilimleri
Bölüm REVIEW ARTICLE
Yazarlar

Damla Çınar Bu kişi benim 0000-0003-4720-9592

Sedanur Sarı Bu kişi benim 0000-0003-4720-9592

Hüseyin Alkan Bu kişi benim 0000-0001-9927-8595

Kübra Buket Ay Bu kişi benim 0000-0002-3876-2700

Enes Borcaktepe Bu kişi benim 0000-0003-4756-7795

Ahmet Yiğit Duyum 0000-0002-0232-0089

Sude Sevcan Filikçi Bu kişi benim 0000-0002-2123-2498

Eren Gençer Bu kişi benim 0000-0002-6808-4795

Çağla Senem Bu kişi benim 0000-0001-6239-8323

Serhat Soylu Bu kişi benim 0000-0001-9392-8825

Şeyma Tuna Bu kişi benim 0000-0002-6848-6612

Rabia Tuncer Bu kişi benim 0000-0002-5417-9574

Mehmet Emin Yazıcı Bu kişi benim 0000-0001-7825-931X

Emre Altıntaş Bu kişi benim 0000-0002-6797-3937

Murat Gül 0000-0002-6657-6227

Yayımlanma Tarihi 22 Eylül 2021
Gönderilme Tarihi 13 Haziran 2021
Yayımlandığı Sayı Yıl 2021 Cilt: 2 Sayı: 3

Kaynak Göster

APA Çınar, D., Sarı, S., Alkan, H., Ay, K. B., vd. (2021). Non-Surgical Treatment Options for Peyronie’s Disease. Archives of Current Medical Research, 2(3), 136-145.
 Kapak Resmi İndir

Archives of Current Medical Research (ACMR) provides instant open access to all content, bearing in mind the fact that presenting research

free to the public supports a greater global exchange of knowledge.

http://www.acmronline.org/